MK 0773

Drug Profile

MK 0773

Alternative Names: MK-0773

Latest Information Update: 22 Sep 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GTx
  • Developer Merck & Co
  • Class Azasteroids; Osteoporosis therapies; Small molecules
  • Mechanism of Action Selective androgen receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Muscular atrophy

Most Recent Events

  • 17 Mar 2010 GTx and Merck terminate licensing agreement
  • 18 Jun 2008 Pharmacodynamics and safety data from a phase I trial in healthy postmenopausal women presented at The Endocrine Society's 90th Annual Meeting (ENDO-2008)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top